Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003887
Status:
COMPLETED
Last Update Posted:
2011-11-30
First Post:
1999-11-01
Brief Title:
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
Sponsor:
Fred Hutchinson Cancer Center
Organization:
Fred Hutchinson Cancer Center
Study Overview
Official Title:
Donor Lymphocyte Infusion DLI as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE White blood cells from donors may be able to kill cancer cells in patients with cancer that has recurred following bone marrow or peripheral stem cell transplantation
PURPOSE Phase II trial to study the effectiveness of donated white blood cells in treating patients who have relapsed cancer following transplantation of donated bone marrow or peripheral stem cells
PURPOSE Phase II trial to study the effectiveness of donated white blood cells in treating patients who have relapsed cancer following transplantation of donated bone marrow or peripheral stem cells
Detailed Description:
OBJECTIVES I Offer donor lymphocyte infusion as adoptive immunotherapy in patients with relapsed malignancies after allogeneic bone marrow or peripheral blood stem cell transplantation and who are not eligible for other FHCRC protocols
OUTLINE Patients with rapidly progressive disease receive reinduction chemotherapy and radiotherapy prior to study therapy Donor lymphocyte infusions DLI begin after recovery from chemotherapy or sooner if clinically indicated Patients receive 1 or more DLI from the original donor Patients are followed monthly for 3 months then every 3-6 months for 9 months
PROJECTED ACCRUAL An unlimited number of patients will be accrued for this study
OUTLINE Patients with rapidly progressive disease receive reinduction chemotherapy and radiotherapy prior to study therapy Donor lymphocyte infusions DLI begin after recovery from chemotherapy or sooner if clinically indicated Patients receive 1 or more DLI from the original donor Patients are followed monthly for 3 months then every 3-6 months for 9 months
PROJECTED ACCRUAL An unlimited number of patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067056 | REGISTRY | PDQ | None |
| FHCRC-60003 | None | None | None |
| NCI-H99-0031 | None | None | None |